The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Allurion Technologies, Inc. (ALUR) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Allurion Technologies, Inc. is a member of our Medical group, which includes 925 different companies and currently sits at #8 in the Zacks Sector Rank. The Zacks Sector Rank ...

Dentsply International (XRAY) came out with quarterly earnings of $0.27 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.57%. A quarter ago, it was expected that this dental products manufacturer would post earnings of $0.45 per share when it actually produced earnings of $0.37, delivering a surprise of -17.78%.Over the las ...

Merit Medical (MMSI) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.93 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +8.90%. A quarter ago, it was expected that this maker of disposable medical devices would post earnings of $0.82 per share when it actually produced earnings of $0.92, delivering a surprise of +12.2%.Over the last f ...

Henry Schein (HSIC) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.3 per share. This compares to earnings of $1.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.08%. A quarter ago, it was expected that this health care products maker would post earnings of $1.27 per share when it actually produced earnings of $1.38, delivering a surprise of +8.66%.Over the last four quarter ...

Company Performance - Adlai Nortye Ltd. Sponsored ADR (ANL) has returned approximately 590.8% year-to-date, significantly outperforming the average gain of 2.3% in the Medical sector [4] - The Zacks Consensus Estimate for ANL's full-year earnings has increased by 33.3% over the past quarter, indicating improved analyst sentiment and earnings outlook [4] Industry Ranking - Adlai Nortye Ltd. is part of the Medical - Biomedical and Genetics industry, which consists of 447 stocks and currently ranks 86 in the Zacks Industry Rank [6] - The average gain for stocks in the Medical - Biomedical and Genetics industry this year is 9%, further highlighting ANL's superior performance [6] Sector Overview - The Medical group, which includes ANL, ranks 9 within the Zacks Sector Rank, which evaluates 16 different groups based on the average Zacks Rank of individual stocks [2] - Another stock in the Medical sector, Cardinal Health, has a year-to-date return of 9.5% and a Zacks Rank of 1 (Strong Buy), indicating strong performance within the sector [5][7]

Core Viewpoint - The comparison between Merit Medical (MMSI) and Straumann Holding AG (SAUHY) indicates that MMSI is currently viewed as the better option for investors seeking undervalued stocks due to its stronger earnings estimate revisions and favorable valuation metrics [1][3]. Group 1: Zacks Rank and Earnings Estimates - MMSI has a Zacks Rank of 2 (Buy), while SAUHY has a Zacks Rank of 3 (Hold), suggesting that MMSI's earnings estimate revision activity is more favorable [3]. - The Zacks Rank system emphasizes stocks with strong earnings estimate revision trends, which is a positive indicator for MMSI [2]. Group 2: Valuation Metrics - MMSI has a forward P/E ratio of 20.07, compared to SAUHY's forward P/E of 28.57, indicating that MMSI may be undervalued relative to SAUHY [5]. - The PEG ratio for MMSI is 1.95, while SAUHY's PEG ratio is 2.78, further supporting the notion that MMSI offers better value based on expected EPS growth [5]. - MMSI's P/B ratio stands at 3.15, significantly lower than SAUHY's P/B of 8.14, reinforcing the argument for MMSI being the more attractive investment option [6]. Group 3: Value Grades - Based on various valuation metrics, MMSI holds a Value grade of B, while SAUHY has a Value grade of C, indicating that MMSI is perceived as a better value investment [6].

Core Insights - West Pharmaceutical Services (WST) reported quarterly earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $1.83 per share, and showing an increase from $1.82 per share a year ago, resulting in an earnings surprise of +11.21% [1] - The company achieved revenues of $805 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.35% and increasing from $748.8 million year-over-year [2] - West Pharmaceutical has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.64, with expected revenues of $759.74 million, while for the current fiscal year, the EPS estimate is $7.67 on revenues of $3.24 billion [7] - The company's favorable estimate revisions trend prior to the earnings release has resulted in a Zacks Rank 2 (Buy), suggesting expected outperformance in the near future [6] Industry Context - The Medical - Dental Supplies industry, to which West Pharmaceutical belongs, is currently ranked in the top 33% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

分组1 - Becton Dickinson (BDX) reported quarterly earnings of $2.91 per share, exceeding the Zacks Consensus Estimate of $2.82 per share, but down from $3.43 per share a year ago, representing an earnings surprise of +3.35% [1] - The company achieved revenues of $5.25 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.03% and showing an increase from $5.17 billion year-over-year [2] - Becton Dickinson has outperformed the S&P 500 with an 8.2% increase in shares since the beginning of the year, compared to the S&P 500's gain of 1.3% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $3.34 on revenues of $5.51 billion, and for the current fiscal year, it is $14.84 on revenues of $22.45 billion [7] - The Medical - Dental Supplies industry, to which Becton Dickinson belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Viewpoint - The market anticipates West Pharmaceutical Services (WST) to report a year-over-year earnings increase driven by higher revenues in its upcoming earnings report for the quarter ended December 2025 [1] Group 1: Earnings Expectations - The consensus estimate for quarterly earnings is $1.83 per share, reflecting a year-over-year change of +0.6% [3] - Expected revenues are projected at $794.26 million, which is a 6.1% increase from the same quarter last year [3] Group 2: Estimate Revisions and Predictions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] - West Pharmaceutical's Most Accurate Estimate is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -0.78%, suggesting a bearish sentiment among analysts [11] Group 3: Historical Performance - In the last reported quarter, West Pharmaceutical exceeded the expected earnings of $1.67 per share by delivering $1.96, resulting in a surprise of +17.37% [12] - The company has beaten consensus EPS estimates in all four of the last quarters [13] Group 4: Market Sentiment and Stock Movement - The stock may experience upward movement if the upcoming earnings report exceeds expectations, while a miss could lead to a decline [2] - Despite a potential earnings beat, other factors may influence stock performance, making it essential to consider broader market conditions [14][16]

分组1 - Cardinal Health reported quarterly earnings of $2.63 per share, exceeding the Zacks Consensus Estimate of $2.39 per share, and up from $1.93 per share a year ago, representing an earnings surprise of +9.86% [1] - The company achieved revenues of $65.63 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.90%, and an increase from $55.26 billion year-over-year [2] - Cardinal has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates two times during the same period [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call and the sustainability of earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.78 on revenues of $62.78 billion, and for the current fiscal year, it is $10.04 on revenues of $259.68 billion [7] - The Medical - Dental Supplies industry, to which Cardinal belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook for the sector [8]